Nathanael Gray of DFCI to Speak at the 7th Protein Kinases Conference (May 30-31, 2012 in Boston, MA)
Nathanael Gray, Principal Investigator, Biological Chemistry & Molecular Pharmacology at Dana Farber Cancer Institute to give a Featured Presentation on "Development and Characterization of Covalent Kinase Inhibitors" at the 7th Protein Kinases in Drug Discovery Conference (May 30-31, 2012 in Boston, MA)
- (1888PressRelease) March 22, 2012 - Dr. Gray will describe two distinct and general methods for efficiently developing novel covalent inhibitors with examples provided for T790M EGFR, FGFR and JNK. His presentation will discuss a broad survey of kinase potential targetable by covalent inhibitors, a description of general approaches for covalent kinase modification, specific examples of covalent inhibitors of T790M EGFR, FGFR and JNK, and examples for how covalent inhibitors can be characterized.
GTCbio is proud to present our 7th Protein Kinases in Drug Discovery Conference in Boston, MA. We will bring together industry leaders from major pharmaceutical companies, biotech companies as well as top researchers from academia and government to provide a better understanding of the complex activities of kinases and some solutions to the challenges associated with kinase drug development. The meeting will offer an intimate forum to engage in discourse with other distinguished researchers involved in the most cutting-edge kinase work.
Representatives from top companies and experts in the field of Protein Kinases scheduled to speak at the conference include ArQule, Avila, Beactica AB, Amgen, Bristol-Myers-Squibb, Eli Lilly, Pfizer, Roche, Merck and more!
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam